A photo of Jose Cancelas Perez.

Director, Hoxworth Blood Center

Leader, Stem Cell Program

Incumbent, Beatrice C. Lampkin Endowment for Stem Cell and Hematotherapy

Professor, UC Department of Pediatrics

513-558-1324

513-558-1522

Biography & Affiliation

Clinical Interests

Hematopoietic stem cell proliferation and differentiation

Academic Affiliation

Professor, UC Department of Pediatrics

Divisions

Experimental Hematology and Cancer Biology, Cancer and Blood Diseases, Global Health

Science Blog

A Cold-Blooded Concept: Launching a Method for Safer, Long-Lasting Platelet Storage

Emergency and Critical Care

A Cold-Blooded Concept: Launching a Method for Safer, Long-Lasting Platelet Storage

Yi Zheng, PhD, Jose A. Cancelas Perez, MD, PhD7/1/2019

Education

MD: Autonomous University of Madrid, Spain, 1989.

Residency: Hematology and Hematotherapy, University of Alcala de Henares, Madrid, Spain, 1993.

PhD: Faculty of Medicine, University of Alcala de Henares, Madrid, Spain, 1996.

Publications

Selected Publication

Transfusion of Uncrossmatched Group O Erythrocyte-containing Products Does Not Interfere with Most ABO Typings. Yazer, MH; Spinella, PC; Doyle, L; Kaufman, RM; Dunn, R; Hess, JR; Filho, LA; Fontaine, M; Gathof, B; Jackson, B; et al. Anesthesiology. 2020; 132:525-534.

Gap junctions in the bone marrow lympho-hematopoietic stem cell niche, leukemia progression, and chemoresistance. Singh, AK; Cancelas, JA. International Journal of Molecular Sciences. 2020; 21:796-796.

IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models. Gasilina, A; Premnauth, G; Gurjar, P; Biesiada, J; Hegde, S; Milewski, D; Ma, G; Kalin, TV; Merino, E; Meller, J; et al. PLoS ONE. 2020; 15:e0229801-e0229801.

NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation. Yu, Y; Choi, K; Wu, J; Andreassen, PR; Dexheimer, PJ; Keddache, M; Brems, H; Spinner, RJ; Cancelas, JA; Martin, LJ; et al. Acta Neuropathologica. 2020; 139:157-174.

Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026). Atreya, C; Glynn, S; Busch, M; Kleinman, S; Snyder, E; Rutter, S; AuBuchon, J; Flegel, W; Reeve, D; Devine, D; et al. Transfusion. 2019; 59:3002-3025.

Ubiquitination is not omnipresent in myeloid leukemia. Nayak, RC; Cancelas, JA. Haematologica: the hematology journal. 2019; 104:1694-1696.

Neutrophils Derived from Genetically Modified Human Induced Pluripotent Stem Cells Circulate and Phagocytose Bacteria In Vivo. Trump, LR; Nayak, RC; Singh, AK; Emberesh, S; Wellendorf, AM; Lutzko, CM; Cancelas, JA. Stem Cells Translational Medicine. 2019; 8:557-567.

IODVA1, a Guanidinobenzimidazole Derivative with in vivo Activity Against Ras-Driven Cancer Models. Gasilina, A; Premnauth, G; Gurjar, P; Biesiada, J; Hegde, S; Milewski, D; Ma, G; Kalin, TV; Merino, E; Meller, J; et al. 2019.

Future of platelet formulations with improved clotting profile: a short review on human safety and efficacy data. Cancelas, JA. Transfusion. 2019; 59:1467-1473.

The signaling axis atypical protein kinase C lambda/iota-Satb2 mediates leukemic transformation of B-cell progenitors. Nayak, RC; Hegde, S; Althoff, MJ; Wellendorf, AM; Mohmoud, F; Perentesis, J; Reina-Campos, M; Reynaud, D; Zheng, Y; Diaz-Meco, MT; et al. Nature Communications. 2019; 10.